Tarsus Pharmaceuticals, Inc.
TARS
Kedudukan dalam Saham
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$71.12
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$3.33B
Perubahan (1 hari)
2.33%
Perubahan (1 tahun)
0.42%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Hasil untuk Tarsus Pharmaceuticals, Inc. (TARS)
Hasil pada Jun 2026 TTM: $606.33M
Menurut laporan kewangan terkini daripada Tarsus Pharmaceuticals, Inc., hasil semasa syarikat (TTM) ialah $606.33M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $17.45M penurunan berbanding hasil pada tahun 2022 iaitu $25.82M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 893.07% |
NL
|
